Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage - PubMed (original) (raw)
- PMID: 3092099
Clinical Trial
Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage
D N Pfohl et al. NIDA Res Monogr. 1986.
Abstract
In summary, evidence is presented associating typically asymptomatic and reversible elevations of serum transaminase values with high daily dosages of naltrexone. Statistical significance was found only between placebo and the 300 mg dosage. Subjects aged 40 years and over were significantly more likely to develop this finding than younger subjects. All subjects with significant elevations of transaminase values in these studies took daily naltrexone dosages higher than recommended for opioid addiction. The daily dosage of naltrexone recommended for opioid addiction did not cause abnormalities of serum transaminase values in these studies.
Similar articles
- [The role of opioid antagonists in the treatment of obesity. Results of a clinical trial with naltrexone].
Novi RF, Lamberto M, Visconti P, Maurino M, Ardizzone A, Mantovan M, Meluzzi A, Francesetti G, Molinatti GM. Novi RF, et al. Minerva Endocrinol. 1990 Apr-Jun;15(2):121-3. Minerva Endocrinol. 1990. PMID: 2098653 Clinical Trial. Italian. - A controlled trial of naltrexone in obese humans.
Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C. Malcolm R, et al. Int J Obes. 1985;9(5):347-53. Int J Obes. 1985. PMID: 3908352 Clinical Trial. - Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.
O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O'Connor PG. O'Malley SS, et al. Arch Intern Med. 2003 Jul 28;163(14):1695-704. doi: 10.1001/archinte.163.14.1695. Arch Intern Med. 2003. PMID: 12885685 Clinical Trial. - Evaluation of abnormal liver tests.
Fregia A, Jensen DM. Fregia A, et al. Compr Ther. 1994;20(1):50-4. Compr Ther. 1994. PMID: 8137620 Review. - Mildly elevated liver transaminase levels in the asymptomatic patient.
Giboney PT. Giboney PT. Am Fam Physician. 2005 Mar 15;71(6):1105-10. Am Fam Physician. 2005. PMID: 15791889 Review.
Cited by
- Manipulation of the Gut Microbiome Alters Acetaminophen Biodisposition in Mice.
Malfatti MA, Kuhn EA, Murugesh DK, Mendez ME, Hum N, Thissen JB, Jaing CJ, Loots GG. Malfatti MA, et al. Sci Rep. 2020 Mar 12;10(1):4571. doi: 10.1038/s41598-020-60982-8. Sci Rep. 2020. PMID: 32165665 Free PMC article. - The relationship between opioid and sugar intake: review of evidence and clinical applications.
Mysels DJ, Sullivan MA. Mysels DJ, et al. J Opioid Manag. 2010 Nov-Dec;6(6):445-52. doi: 10.5055/jom.2010.0043. J Opioid Manag. 2010. PMID: 21269006 Free PMC article. Review. - Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.
King A, Cao D, Vanier C, Wilcox T. King A, et al. Alcohol Clin Exp Res. 2009 Jun;33(6):1044-50. doi: 10.1111/j.1530-0277.2009.00925.x. Epub 2009 Mar 19. Alcohol Clin Exp Res. 2009. PMID: 19302083 Free PMC article. Clinical Trial. - Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA; Veterans Aging Cohort Study Team. Tetrault JM, et al. Alcohol Clin Exp Res. 2012 Feb;36(2):318-24. doi: 10.1111/j.1530-0277.2011.01601.x. Epub 2011 Jul 28. Alcohol Clin Exp Res. 2012. PMID: 21797892 Free PMC article. - Maintenance medication for opiate addiction: the foundation of recovery.
Bart G. Bart G. J Addict Dis. 2012;31(3):207-25. doi: 10.1080/10550887.2012.694598. J Addict Dis. 2012. PMID: 22873183 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical